<DOC>
	<DOCNO>NCT01191203</DOCNO>
	<brief_summary>The IUD extremely effective method contraception yet woman use worldwide . Considered safe use HIV+ woman , study evaluate use among use antiretroviral therapy . The prior randomize trial look IUD compare hormonal contraception note high rate IUD discontinuation . Understanding IUD acceptability continuation critical improve utilization . - Objective 1 : Determine WHO medical eligibility willingness IUD placement - Objective 2 : Compare method-related side effect adverse event - Objective 3 : Assess 1-year acceptability continuation rate Methods : To address objective investigator design two Phase Study : - A cross-sectional screening evaluate contraceptive medical eligibility desirability - A randomized control trial compare acceptability adherence DMPA compare Copper IUD : enrol 200 woman stable antiretroviral therapy follow 1 year</brief_summary>
	<brief_title>Randomized Control Trial Copper Intrauterine Device Depo-medroxyprogesterone Acetate ( DMPA ) HIV+ Women Malawi</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Copper</mesh_term>
	<criteria>Can provide informed consent Women age 1845 Known HIV + status antiretroviral therapy least 6 month Not currently pregnant Willing initiate either DMPA CuT380AIUD . Women currently use DMPA CuT380AIUD exclude Do desire become pregnant within next 12 month Intend stay Lilongwe region duration study No known uterine anomaly base upon history Greater equal 4 week post partum No known suspect genital tract cancer No evidence current pelvic inflammatory disease cervicitis . Women cervicitis time examination treat antibiotic eligibility reassess followup visit least 7 day treatment No pelvic inflammatory disease within prior 3 month No contraindication DMPA CuT380AIUD per WHO medical eligibility criterion Malawi National Reproductive Health Service Delivery Guidelines , 2007 Based clinical assessment , condition would preclude start study intervention Women age young than18 old 45 Known HIV + status antiretroviral therapy le 6 month antiretroviral therapy Pregnant Uterine anomaly Less 4 week post partum Suspected genital tract cancer â€¢Current STI PID</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Acceptability Adherence method</keyword>
</DOC>